1. Home
  2. STEM vs RLYB Comparison

STEM vs RLYB Comparison

Compare STEM & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stem Inc.

STEM

Stem Inc.

HOLD

Current Price

$7.36

Market Cap

78.4M

Sector

Technology

ML Signal

HOLD

Logo Rallybio Corporation

RLYB

Rallybio Corporation

HOLD

Current Price

$16.00

Market Cap

92.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STEM
RLYB
Founded
2009
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
78.4M
92.3M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
STEM
RLYB
Price
$7.36
$16.00
Analyst Decision
Hold
Analyst Count
3
0
Target Price
$13.33
N/A
AVG Volume (30 Days)
136.9K
57.6K
Earning Date
05-06-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$156,266,000.00
$858,000.00
Revenue This Year
$2.77
N/A
Revenue Next Year
$14.65
N/A
P/E Ratio
N/A
N/A
Revenue Growth
8.08
43.00
52 Week Low
$6.04
$0.32
52 Week High
$32.23
$17.57

Technical Indicators

Market Signals
Indicator
STEM
RLYB
Relative Strength Index (RSI) 37.31 64.94
Support Level $7.20 $0.57
Resistance Level $10.96 $17.57
Average True Range (ATR) 0.55 0.47
MACD -0.01 -0.17
Stochastic Oscillator 13.14 67.03

Price Performance

Historical Comparison
STEM
RLYB

About STEM Stem Inc.

Stem Inc is a provider of energy storage systems. The company bundles third-party hardware with its proprietary Athena software to provide customers a turnkey solution. Stem sells its solutions to commercial and industrial customers as well as independent power producers and renewable developers. Its solutions help customers maximize renewable energy generation and help build a cleaner and more resilient grid. The Company operates as one operating segment that is focused exclusively on technology services that transform the way energy is distributed and consumed.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Share on Social Networks: